OPKO Health (NASDAQ:OPK) Sets New 12-Month Low - Here's What Happened
OPKO Health (NASDAQ:OPK) shares hit a new 52-week low of $1.10 on Monday, closing at $1.1150. Analysts largely have a "Hold" rating with a $2.03 target, though some have issued "sell" calls and lowered price targets. Despite beating EPS estimates in its last quarter, the company's revenue dropped 19.1% year-over-year, and it remains unprofitable.
OPKO Health Inc Stock: Business Model, Growth Drivers, and Key Investor Considerations in Diagnostics and Pharmaceuticals
OPKO Health Inc. (OPK) operates in biotechnology with dual segments: diagnostics through BioReference Health and pharmaceuticals. The company's strategy focuses on innovative testing solutions and therapeutic developments, leveraging acquisitions and strategic partnerships. Key investor considerations include the stability of its diagnostics business, the potential upside from its pharmaceutical pipeline targeting endocrine and renal disorders, and strong institutional backing, balanced against competitive and regulatory risks.
OPKO Health Inc stock faces pressure amid insider buying and Labcorp deal aftermath
OPKO Health Inc. shares are experiencing pressure despite CEO Phillip Frost's recent share purchases and the positive impact of its BioReference oncology diagnostics business sale to Labcorp. While the divestiture boosted Q3 2025 profits, the company still faces ongoing losses and a significant foreign tax assessment. US investors are monitoring OPKO's pipeline progress in therapeutics and its strengthened cash position for potential turnaround, with insider buying signaling confidence and technical indicators pointing to a strong buy in the near term.
OPKO Health Inc stock faces analyst cuts as earnings outlook darkens amid biotech pressures
OPKO Health Inc (NASDAQ:OPK) is facing significant analyst downgrades, with Zacks Research slashing Q3 2026 EPS estimates to ($0.07) from ($0.06) and projecting full-year FY2026 losses of ($0.29) per share. These revisions are driven by persistent revenue pressures in its diagnostics business and slow pharmaceutical ramp-up, despite strategic asset sales and insider purchases. While the company's valuation is compressed and institutional ownership remains solid, investor focus is on pipeline progress and the ability to stem ongoing losses amidst a high-interest-rate environment.
OPKO Health Inc stock faces analyst cuts as earnings outlook darkens amid biotech pressures
OPKO Health Inc (NASDAQ:OPK) is facing significant analyst downgrades, with Zacks Research slashing Q3 2026 EPS estimates to -0.07, highlighting broader profitability challenges. The biotech firm is grappling with revenue pressures in its diagnostics business and slow pharmaceutical ramp-up, leading to caution from analysts like Barrington Research, which cut its price target to $1.50. Despite strategic asset sales and insider confidence, the stock's future hinges on stabilizing earnings and pipeline catalysts amid a volatile biotech market.
OPKO Health (NASDAQ:OPK) Director Buys $11,400.00 in Stock
OPKO Health (NASDAQ:OPK) Director John Paganelli bought 10,000 shares of the company's stock for $1.14 per share, totaling $11,400. This purchase increased his stake by 2.6% to 394,340 shares. Despite beating quarterly EPS and revenue estimates, the company's revenue was down 19.1% year-over-year, and its shares traded near their 52-week low.
Opko Health director Paganelli buys $11,350 in company stock
Opko Health director John A. Paganelli recently purchased 10,000 shares of the company's common stock for $11,350, with the stock trading near its 52-week low. This insider buying, along with aggressive share buybacks, suggests the stock is undervalued according to InvestingPro analysis. The company also recently exceeded Q4 2025 earnings expectations and appointed a new board director.
Opko Health (OPK) director adds 10,000 shares in open-market buy
Opko Health director John A. Paganelli recently purchased 10,000 shares of the company's common stock in an open-market transaction at $1.135 per share. Following this acquisition, Paganelli directly holds 394,340 shares. An additional 9,175 shares are held by his spouse, for which he disclaims beneficial ownership.
Barrington Lowers PT on OPKO Health (OPK), Keeps a Buy
Barrington has lowered its price target on OPKO Health (NASDAQ: OPK) from $2.25 to $1.50 but maintained a Buy rating, despite the company topping fiscal Q4 2025 revenue estimates. The firm expressed concern that "other revenue" primarily saved the quarter, a performance level deemed unsustainable. OPKO’s Q4 2025 revenue declined 19.12% year-over-year but beat consensus, while EPS also exceeded expectations.
OPKO appoints Subbarao V. Uppaluri to Board following Richard Krasno's passing
OPKO Health (OPK) has appointed Subbarao V. Uppaluri, Ph.D., to its Board of Directors, effective March 18, 2026. This appointment fills the vacancy left by the passing of Dr. Richard Krasno. Uppaluri is also expected to be appointed to the Compensation Committee.
OPKO Health (OPK) appoints former CFO Subbarao Uppaluri to board
OPKO Health, Inc. has appointed Subbarao V. Uppaluri, Ph.D., its former Senior Vice President and Chief Financial Officer, to its Board of Directors as an independent director, effective March 18, 2026. Dr. Uppaluri will fill a vacancy left by the passing of Dr. Richard Krasno and is expected to join the Compensation Committee. The board determined Uppaluri meets independence criteria from the SEC and Nasdaq, and there are no related-party transactions to disclose.
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPKO Health, Inc. (OPK) is well-positioned for future growth due to the potential of RAYALDEE, strategic partnerships, and a streamlined BioReference division. Despite restructuring leading to an initial revenue decline and continued operating losses, strong contributions from collaborations with Pfizer and Lilly, alongside advancements in its ModeX pipeline, are expected to bolster its financial performance. The company’s long-term outlook appears positive, but it faces challenges from stiff competition, over-reliance on RAYALDEE, and near-term revenue recovery hurdles.
OPKO Health (OPK) reports Q4 loss, tops revenue estimates
OPKO Health (OPK) reported a fourth-quarter loss that was wider than anticipated but exceeded revenue estimates. The company posted a loss of $0.09 per share, missing the Zacks Consensus Estimate of a $0.08 loss, while revenues of $223.70 million surpassed expectations. Despite the revenue beat, the stock experienced a slight decline in after-hours trading.
Opko Health Inc. (OPK) builds value through partnerships and innovation
This article discusses how Opko Health Inc. (OPK) is strategically using partnerships and innovative approaches to enhance its value. By focusing on collaborations, the company aims to strengthen its product pipeline and market presence. The strategy highlights a commitment to growth through external alliances and internal research and development.
OPKO Health (NASDAQ:OPK) Given New $1.50 Price Target at Barrington Research
Barrington Research has lowered its price target for OPKO Health (NASDAQ:OPK) to $1.50 from $2.25, while maintaining an "outperform" rating, indicating a potential upside of 25.5% from its previous close. Despite a revenue decline of 19.1% year-over-year, OPKO Health recently beat EPS estimates. The company currently holds a consensus rating of "Hold" among analysts, with a market capitalization of approximately $917 million.
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
OPKO Health, Inc. announced its participation in the Jefferies Biotech on the Beach Summit scheduled for March 10-11, 2026, in Miami. Management will hold one-on-one meetings with investors on March 11th. Interested investors are encouraged to contact their Jefferies representative to schedule a meeting.
OPKO Health (OPK) Loss Worsens To US$0.30 TTM EPS Challenging Turnaround Narratives
OPKO Health (OPK) reported a worsening loss for FY 2025, with Q4 revenue at US$148.45 million and a US$0.04 basic EPS loss, contributing to a US$0.30 TTM EPS loss. Despite some revenue growth on a trailing basis, the company's profitability remains under pressure, with losses growing annually by 24.6% over the past five years. Analysts predict continued unprofitability for the next three years, challenging a bullish narrative that relies on a significant shift from the current loss-making profile.
OPKO Health, Inc. (NASDAQ:OPK) Q4 2025 Earnings Call Transcript
OPKO Health (NASDAQ:OPK) reported its Q4 2025 financial results, with an EPS of $-0.04089, beating expectations of $-0.07. The company highlighted significant strategic advancements, including the divestiture of BioReference's oncology division, progress in its ModeX therapeutic pipeline with multiple clinical-stage programs, and a new collaboration with Regeneron. OPKO also emphasized a strong cash position and a commitment to shareholder returns through share repurchases, while forecasting total revenue for Q1 2026 between $125 million and $140 million.
Biotech investors meet OPKO Health at Miami beach summit
OPKO Health announced its participation in the Jefferies Biotech on the Beach Summit on March 10-11, 2026, in Miami, where company management will hold one-on-one meetings with investors. The news follows a series of investor relations events and financial updates for OPKO, with past event and partnership headlines seeing mixed market reactions. Investors are encouraged to contact their Jefferies representative to schedule meetings with OPKO management during the summit.
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
OPKO Health, Inc. announced its participation in the Jefferies Biotech on the Beach Summit, scheduled for March 10-11, 2026, in Miami. Management will hold one-on-one meetings with registered investors on March 11th. Investors interested in scheduling a meeting are advised to contact their Jefferies representative.
Opko Health Bets on Pipeline as Near-Term Profits Fade
Opko Health's latest earnings call revealed a strategy of prioritizing pipeline development over short-term profits, despite facing revenue pressure and a return to quarterly losses. The company is accelerating its ModeX pipeline, deepening partnerships with blue-chip companies like Regeneron, and leveraging government funding, all while maintaining a strong balance sheet and aggressive capital returns. Although 2026 is projected to be an investment-heavy year with planned operating losses, Opko aims for long-term value creation through its expanding pipeline and strategic collaborations.
OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts
OPKO Health (OPK) reported a Q4 2025 loss per share of 4 cents, beating the Zacks Consensus Estimate, despite a 19.1% year-over-year revenue decrease to $148.5 million. The company's Diagnostics segment saw reduced service revenues, while Pharmaceuticals recorded product revenue growth,
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
OPKO Health, Inc. (Nasdaq: OPK) announced its participation in the Jefferies Biotech on the Beach Summit, scheduled for March 10-11, 2026, in Miami. Management will be holding one-on-one meetings with investors on March 11th. Investors interested in meeting with OPKO management should contact their Jefferies representative.
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
OPKO Health, Inc. announced its participation in the Jefferies Biotech on the Beach Summit on March 10-11, 2026. Management will hold one-on-one meetings with investors registered for the event on March 11th. Investors interested in meeting with OPKO management should contact their Jefferies representative.
OPKO Health Inc reports results for the quarter ended December 31 - Earnings Summary
OPKO Health Inc has released its earnings summary for the quarter that ended on December 31. The report, published by Refinitiv, is a concise overview of the company's financial performance.
OPKO Health inks $1B-plus Regeneron antibody pact in Q4 update
OPKO Health reported Q4 2025 financial results, with consolidated revenues of $148.5 million and a net loss of $31.3 million, primarily due to asset sales. Despite the revenue decline, the company highlighted a significant new research collaboration with Regeneron Pharmaceuticals potentially exceeding $1 billion, along with progress in its pipeline, including vaccine trials and new antibody programs for oncology and infectious diseases. OPKO also issued full-year 2026 revenue guidance between $530 million and $560 million, maintaining a strong cash position of $369.1 million.
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. reported its business highlights and financial results for Q4 2025 and provided financial guidance for Q1 and full year 2026. Key highlights include a research collaboration with Regeneron Pharmaceuticals for multispecific antibodies, progress in vaccine and T-cell engager trials, and an expanded partnership with Entera Bio for a hypoparathyroidism treatment. The company reported a consolidated net loss of $31.3 million for Q4 2025 due to decreased revenues primarily from asset sales and increased costs in pharmaceuticals, while providing revenue guidance between $530 million and $560 million for full-year 2026.
Income Statement
This document presents the consolidated income statement for OPKO Health, Inc. (OPK) for the 12 months ended December 31, 2025, 2024, and 2023. It details revenues, costs and expenses, operating loss, other income and expenses, and ultimately the net loss and loss per share for these periods, along with definitional details for various financial terms. The company reported a net loss of $(225,680) in 2025, compared to $(53,224) in 2024 and $(188,863) in 2023.
OPKO Health: Fourth Quarter Financial Overview
Opko Health Inc. reported a net loss of $31.3 million, or 4 cents per share, for the fourth quarter, which was better than analysts' expected loss of 7 cents per share. The company generated $148.5 million in revenue, surpassing analyst expectations of $138.1 million. For the full year, Opko Health experienced a total loss of $225.7 million with revenues of $606.9 million and provided revenue guidance for the upcoming first quarter and full year.
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reported its Q4 2025 financial results and business highlights, including a research collaboration with Regeneron Pharmaceuticals and progress in several drug development programs. The company saw consolidated total revenues of $148.5 million but experienced a net loss of $31.3 million for the quarter. OPKO also provided financial guidance for the first quarter and full year 2026.
OPKO Health, Inc. Reports Q4 2025 Financial Results and 2026 Guidance, Highlights Key Collaborations and Innovations
OPKO Health, Inc. reported a consolidated total revenue of $148.5 million for Q4 2025, a decrease from the previous year, and a net loss of $31.3 million. Despite the financial decline, the company highlighted significant advancements including a research collaboration with Regeneron Pharmaceuticals, progress in its oncology pipeline with MDX2003 entering Phase 1 studies, and an expanded partnership with Entera Bio for an oral long-acting PTH tablet. OPKO provided 2026 guidance, expecting total revenues between $530 million and $560 million.
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. announced its fourth-quarter and full-year 2025 financial results, alongside business highlights that include new collaborations and advancements in its drug pipeline. Key developments feature a research collaboration with Regeneron Pharmaceuticals, progress in Merck's Epstein-Barr virus vaccine trial, and advancements in multiple trispecific and tetraspecific antibody programs for cancer and COVID-19 treatment. The company reported a net loss of $31.3 million for Q4 2025 and provided financial guidance for Q1 and full-year 2026.
OPKO Health Inc expected to post a loss of 7 cents a share - Earnings Preview
OPKO Health Inc is projected to report a loss of 7 cents per share. This information comes from an earnings preview provided by Refinitiv and Reuters. The article is a brief financial news piece focusing on the company's expected earnings.
Opko Health, Inc. (OPK) Stock Analysis: A Closer Look At Its 209% Potential Upside
Opko Health, Inc. (OPK) is analyzed for its significant 209.42% potential upside, based on analyst target prices ranging from $1.60 to $8.50, with an average of $3.56. Despite current financial challenges such as a negative P/E ratio and cash burn, the healthcare company, focusing on diagnostics and pharmaceuticals, holds five out of seven buy ratings. Its strategic focus on innovative treatments and global presence are highlighted as potential catalysts for future growth, appealing to long-term investors with higher risk tolerance.
Opko Health CEO Phillip Frost buys $444,300 in company stock By Investing.com
Phillip Frost, CEO and Chairman of Opko Health, Inc. (NASDAQ:OPK), recently invested $444,300 in company stock, purchasing 500,000 shares at a weighted average price of $0.8886. This significant acquisition, bringing his total holdings to over 210 million shares, is seen as a strong vote of confidence despite the company's volatile stock price and negative P/E ratio. Analysts predict Opko Health will be profitable this year, and the company is trading near its 52-week low.
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages
Seven brokerages have issued a "Hold" recommendation for OPKO Health, Inc. (NASDAQ:OPK), with an average 12-month price target of $2.2833. Analysts' ratings range from "sell" to "strong buy," reflecting varied opinions on the stock. Institutional investors have significantly adjusted their positions, with notable increases in holdings by major firms.
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?
OPKO Health (OPK) is positioned for growth in the coming quarters, driven by the potential of its renal therapy RAYALDEE and strategic partnerships. Despite concerns about competition and over-reliance on RAYALDEE, the company's clinical pipeline includes several advanced programs in oncology, hypoparathyroidism, and metabolic disorders. OPKO Health anticipates 30% growth for fiscal 2026 and has undertaken divestitures to streamline operations and strengthen its balance sheet.
OPKO Health (OPK) Projected to Post Quarterly Earnings on Thursday
OPKO Health (OPK) is expected to announce its Q4 2025 earnings after market close on Thursday, February 26th, with projected EPS of ($0.07) and revenue of $139.757 million. The company has seen significant insider activity, including CEO Phillip Frost's purchase of 580,000 shares, bringing insider ownership to 49.69%. Analysts currently hold a consensus "Hold" rating for OPK, with a price target of $2.28.
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation
Opko Health Inc. (OPK) has received a reiterated Buy rating and a $3 price target from H.C. Wainwright, due to progress in its biological partnerships. The company's subsidiary is expanding collaboration with Entera Bio for an oral, long-acting parathyroid hormone analog, with positive results and an IND filing planned for late 2026. This partnership gives both companies 50% ownership and shared development costs, highlighting OPK's diversified approach in diagnostics and pharmaceuticals.
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation
Opko Health Inc. (OPK) is highlighted as a high-return penny stock due to its partnerships and innovation. H.C. Wainwright reiterated a Buy rating with a $3 price target, citing progress in biological collaborations including an expanded partnership with Entera Bio for a long-acting parathyroid hormone analog. This collaboration aims to transform hypoparathyroidism treatment, with positive preclinical results and an IND filing planned for late 2026, where both companies share 50% ownership and development costs.
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
OPKO Health, Inc. (NASDAQ: OPK) announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the U.S. financial markets close on Thursday, February 26, 2026. Senior management will host a conference call and webcast at 4:30 p.m. Eastern time to provide a business update, discuss results, and offer financial guidance. Participants can pre-register for the call or access it via dial-in or the company's Investor Relations page.
OPKO Health, Inc. to Announce 2025 Financial Results on February 26, 2026
OPKO Health, Inc. will report its operating and financial results for the three and twelve months ending December 31, 2025, on February 26, 2026, after the U.S. market closes. Senior management will host a conference call and live audio webcast at 4:30 p.m. Eastern Time to provide a business update and discuss the results and financial guidance. Interested parties can pre-register for the call or access it via standard dialing, with replays available afterward.
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
OPKO Health, Inc. (NASDAQ: OPK) announced it will report its Q4 and full-year 2025 financial results after the market closes on February 26, 2026. Senior management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide financial guidance. Interested parties can pre-register for the call or access details through the company's investor relations page.
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development
Opko Health (OPK) has expanded its partnership with Entera Bio Ltd. to co-develop an oral long-acting PTH analog for hypoparathyroidism, aiming to file an IND application in late 2026. Both companies will share 50% ownership and development costs for this program. They also maintain their existing 60/40 ownership structure for the oral OXM program for metabolic and fibrotic disorders.
Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism
Opko Health and Entera Bio have expanded their partnership to develop a first-in-class oral, long-acting parathyroid hormone (PTH) tablet for patients suffering from hypoparathyroidism. This collaboration aims to advance a new treatment option for this condition. The news was reported by Refinitiv.
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
OPKO Health and Entera Bio have expanded their partnership to accelerate the development of a first-in-class oral long-acting PTH analog (LA-PTH) for hypoparathyroidism, aiming for an IND application in late 2026. This collaboration, which includes a 50/50 ownership and cost-sharing split for the LA-PTH program, builds on their existing work on an oral oxyntomodulin for metabolic disorders. The companies anticipate providing a more convenient, once-daily tablet treatment, eliminating the need for daily injections currently required for hypoparathyroidism patients.
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board
Entera Bio (NASDAQ: ENTX) has expanded its collaboration with OPKO Health to include the joint development of a daily long-acting PTH tablet for hypoparathyroidism, in addition to their existing GLP-1/glucagon program. Development costs for the new LA-PTH program will be shared equally. Additionally, the company announced the resignation of director Gerald Ostrov and the appointment of Steven D. Rubin as a Class III director, who will also serve as Chairman of the audit committee.
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK)
The article highlights OPKO Health (OPK) as a deeply undervalued company with significant potential due to its partnerships with Merck, Regeneron, and BARDA for developing COVID-19, influenza, and cancer treatments, along with EBV vaccines. The company's financial health is improving with decreasing debt, and analysts project a favorable P/S ratio by 2030. These factors, alongside upcoming clinical trial readouts and its MSTAR platform, suggest an attractive risk/reward profile for long-term investors.
OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of "Hold" from Analysts
Seven analysts have issued ratings for OPKO Health (NASDAQ:OPK), resulting in a consensus "Hold" rating with an average 12-month target price of $2.28. Despite a recent earnings beat of $0.03 EPS, revenue declined by 12.6% year-over-year. Insiders, including CEO Phillip Frost, have been buying shares, with insiders now owning nearly 50% of the company.
OPKO Health, Inc. (NASDAQ:OPK) insiders have recently purchased stock and their bets paid off last week as company hit US$1.0b market cap
Insiders at OPKO Health, Inc. (NASDAQ:OPK) recently purchased company stock, and these investments proved profitable as the company achieved a US$1.0 billion market capitalization last week. Individual insiders collectively own 42% of the company, with CEO Phillip Frost holding 29% of outstanding shares. This significant insider ownership suggests a strong vested interest in the company's growth, and the stock saw a 7.9% gain, benefiting these recent insider purchases.
